PRME:NASDAQPrime Medicine, Inc. Analysis
Data as of 2026-07-21 - not real-time
$3.05
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Prime Medicine (PRME) is currently trading well beneath its short‑ and medium‑term moving averages, with momentum indicators turning bearish. The relative strength index sits in the low‑forties, suggesting limited upside momentum, while the MACD histogram is negative. Volume is rising, indicating renewed trader interest, but the stock exhibits extremely high price volatility and a beta that far exceeds the market, underscoring pronounced price swings.
Fundamentally, the company is cash‑rich yet heavily indebted, with operating and free cash flow deeply negative and margins in the red. The balance sheet shows a modest net cash cushion after debt, but the high debt‑to‑equity ratio and negative return metrics highlight financial strain. The recent arbitration win with Beam Therapeutics removes a legal cloud over its AATD program, providing a tangible catalyst that could support the pipeline’s progress.
Fundamentally, the company is cash‑rich yet heavily indebted, with operating and free cash flow deeply negative and margins in the red. The balance sheet shows a modest net cash cushion after debt, but the high debt‑to‑equity ratio and negative return metrics highlight financial strain. The recent arbitration win with Beam Therapeutics removes a legal cloud over its AATD program, providing a tangible catalyst that could support the pipeline’s progress.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price below key moving averages
- bearish MACD and modest RSI
- rising volume may signal short‑term buying interest
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- legal victory securing the AATD program
- potential upside relative to current price
- industry growth prospects for gene‑editing therapies
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- strategic collaborations with leading biotech partners
- long‑run demand for innovative gene‑editing treatments
- ability to leverage cash position to fund pipeline despite current losses
Key Metrics & Analysis
Financial Health
Revenue Growth-41.10%
P/E Ratio-3.6
ROE-216.06%
ROA-41.46%
Debt/Equity149.30
P/B Ratio7.2
Op. Cash Flow$-156416992
Free Cash Flow$-78317504
Industry P/E28.7
Technical Analysis
TrendNeutral
RSI40.6
Support$3.02
Resistance$4.82
MA 20$3.60
MA 50$3.29
MA 200$3.85
MACDBearish
VolumeIncreasing
Fear & Greed Index89.54
Valuation
Target Price$7.12
Upside/Downside133.34%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.33
Volatility98.24%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.